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Abstract
Background: In rodents treatment with fibrates causes hepatocarcinogenesis, probably as a result
of oxidative stress and an impaired balance between apoptosis and cell proliferation in the liver.
There is some debate whether fibrates could also induce liver cancer in species not responsive to
peroxisome proliferation. In this study the effect of clofibrate treatment on peroxisome
proliferation, production of oxidative stress, gene expression of pro- and anti-apoptotic genes and
proto-oncogenes was investigated in the liver of pigs, a non-proliferating species.
Results: Pigs treated with clofibrate had heavier livers (+16%), higher peroxisome counts (+61%),
higher mRNA concentration of acyl-CoA oxidase (+66%), a higher activity of catalase (+41%) but
lower concentrations of hydrogen peroxide (-32%) in the liver than control pigs (P < 0.05);
concentrations of lipid peroxidation products (thiobarbituric acid-reactive substances, conjugated
dienes) and total and reduced glutathione in the liver did not differ between both groups. Clofibrate
treated pigs also had higher hepatic mRNA concentrations of bax and the proto-oncogenes c-myc
and c-jun and a lower mRNA concentration of bcl-XL than control pigs (P < 0.05).
Conclusion: The data of this study show that clofibrate treatment induces moderate peroxisome
proliferation but does not cause oxidative stress in the liver of pigs. Gene expression analysis
indicates that clofibrate treatment did not inhibit but rather stimulated apoptosis in the liver of
these animals. It is also shown that clofibrate increases the expression of the proto-oncogenes c-
myc and c-jun in the liver, an event which could be critical with respect to carcinogenesis. As the
extent of peroxisome proliferation by clofibrate was similar to that observed in humans, the pig
can be regarded as a useful model for investigating the effects of peroxisome proliferators on liver
function and hepatocarcinogenesis.
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Background
Peroxisome proliferators (PPs) comprise a diverse group
of chemicals, including pharmaceuticals, industrial chem-
icals, endogenous fatty acids and eicosanoids. They bind
to and activate the peroxisome proliferator-activated
receptor (PPAR)-α, a transcription factor belonging to the
nuclear hormone receptor superfamily [1]. Activation of
PPARα causes an increase in the transcription of genes
related to fatty acid transport across the cell membrane,
intracellular lipid trafficking, mitochondrial and peroxi-
somal fatty acid uptake, and both mitochondrial and per-
oxisomal fatty acid β-oxidation [2]. Administration of PPs
to rats and mice typically causes hepatic peroxisome pro-
liferation, hypertrophy, hyperplasia, and hepatocarcino-
genesis [3,4]. PPARα-induced hepatocarcinogenesis in
rats and mice may be mainly due to an increased oxidative
stress caused by peroxisome proliferation and an altera-
tion of the balance between apoptosis and cell prolifera-
tion [5,6]. Treatment with PPs such as fibrates causes a 15
to 20-fold up-regulation of acyl-CoA oxidase (ACO) and
other peroxisomal oxidases that lead to the production of
hydrogen peroxide (H2O2) which under normal non-
induced circumstances can be detoxified by catalase [7,8].
Catalase induction increases only approximately twofold
in response to PPARα agonists in rodents, and the activity
of glutathione peroxidase is often depressed following
long term administration of PPs [9,10]. The capacity of
the H2O2-degrading enzymes therefore may be insuffi-
cient to detoxify the large increase in H2O2. Increased cel-
lular H2O2 could also react with metals and generate
highly reactive hydroxyl radicals that could damage DNA,
proteins or lipids [7]. Indeed, oxidatively damaged DNA
and peroxide-modified lipids have been found in hepato-
cytes of rats treated with PPs [11-13]. Activation of PPARα
also leads to increases in hepatocellular proliferation and
inhibition of apoptosis, and when this occurs in DNA-
damaged cells, it is thought to lead to proliferation of ini-
tiated cells progressing to liver tumour [14,15]. That
PPARα is required to mediate hepatocarcinogenesis by
PPs has been demonstrated in studies with PPARα-null
mice that are refractory to this in response to long term
administration of PPs [15,16].
It is well known that non-human primates and humans
are only weakly responsive to peroxisome proliferation in
comparison to rodents [17,18]. Nevertheless, there is con-
siderable controversy as to whether the administration of
drugs which are ligands for PPARα to humans causes liver
cancer. This is significant because PPARα agonists such as
fibrates have been in clinical use for the treatment of
hyperlipidaemias for many years. The data regarding the
ability of fibrates to cause peroxisome proliferation in
humans are diverse. Examination of liver biopsy samples
from patients receiving therapeutic doses of PPARα ago-
nists showed a slight increase in peroxisome counts [19],
while others showed no increase [20,21]. In non-human
primates, administration of clofibrate induced a moder-
ate, dose-dependent peroxisome proliferation [22-24]. It
is therefore conceivable that cellular events induced by
PPs related to hepatocarcinogenesis in rodents could
occur also in non-proliferating species, albeit probably
less pronounced than in rodents.
Pigs, like humans and non-human primates, are a non-
proliferating species [25]. They may therefore be a valua-
ble model for investigating the effects of PPs on peroxi-
some proliferation and related processes. To our
knowledge, the effect of fibrates on parameters related to
hepatocarcinogenesis has not yet been investigated in
pigs. We therefore treated pigs with clofibrate and deter-
mined hepatic weight, number of peroxisomes and ACO
expression to provide information about the potency of
fibrates to induce peroxisome proliferation in pigs. We
also considered the antioxidant status of the pigs (mRNA
concentrations and activities of various antioxidant
enzymes including catalase, generation of H2O2 in the
liver, concentrations of lipid peroxidation products) to
find out whether clofibrate causes oxidative stress in pig
liver. In order to ascertain whether clofibrate treatment
could affect the balance between cell proliferation and
apoptosis we determined mRNA concentrations of pro-
and anti-apoptotic genes, namely bax, bcl-XL and p53
tumour suppressor gene. It has been shown that the
nuclear factor κB (NF-κB) pathway is important in the
activation of genes that regulate cell proliferation and
apoptosis in various cell types [26,27]. It was shown
recently that NF-κB contributes to the proliferative and
apoptotic changes that occur in liver in response to
fibrates [28]. More recently, it has been demonstrated that
the p50 subunit of the NF-KB family is necessary for the
promotion of hepatocarcinogenesis by PPs [29]. To find
out whether clofibrate treatment activated NF-KB in pig
liver, we determined the mRNA concentration of tumor
necrosis factor α (TNFα), a target gene of NF-KB which has
also been identified as a suppressor of apoptosis and an
inducer of DNA synthesis [30,31]. In rat liver and in
mouse liver epithelial cells, treatment with the PPARα
agonist WY-14,643 strongly up-regulated gene expression
of various proto-oncogenes including c-fos, c-jun and c-
myc [32-35]. In mouse liver cells these changes were fol-
lowed by enhanced DNA synthesis, and it has been con-
cluded that this could play an important role in tumour
promotion by PPs [33]. Whether PPs stimulate expression
of proto-oncogenes in pigs has not yet been investigated.
We therefore also determined gene expression of c-myc, c-
jun and c-fos in liver of pigs treated with clofibrate, which
could be critical with respect to hepatocarcinogenesis.BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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Results
Due to the controlled feeding system, diet intake during
the whole experimental period was identical in both
groups of pigs, being 696 ± 7 g/d in average of the whole
period. Final body weights of the pigs on day 29 did not
differ between the control group and the group treated
with clofibrate (26.0 ± 1.5 kg for control pigs vs. 25.2 ± 1.2
kg for pigs treated with clofibrate, n = 9 in each group).
Pigs treated with clofibrate had higher liver weights
(+16% in absolute terms, +19% in relative terms,
expressed per kg body weight), higher peroxisome counts
in the liver (+61%) (P < 0.05, Table 1). Relative mRNA
concentration of PPARα in liver did not differ between
both groups of pigs (control: 1.00 ± 0.38; clofibrate: 0.92
± 0.20, n = 9, means ± SD) but pigs treated with clofibrate
had a higher relative mRNA concentration of ACO in the
liver (+66%) than control pigs (P < 0.05, Table 1).
As reference values for the expression of enzyme activities,
we determined concentrations of protein in liver homoge-
nate and liver cytosol. Protein concentration in liver
homogenate did not differ between both groups of pigs
(control: 20.8 ± 5.9 mg/g liver; clofibrate: 21.1 ± 5.8 mg/
g liver, n = 9, means ± SD); protein concentration in liver
cytosol was higher in pigs treated with clofibrate than in
control pigs (control: 27.2 ± 2.3 mg/g liver; clofibrate:
30.4 ± 3.0 mg/g liver, n = 9, means ± SD, P < 0.05). Pigs
treated with clofibrate had higher mRNA concentrations
and activities of superoxide dismutase (SOD) (+77% and
+128%, respectively) and catalase (+72% and +41%,
respectively) in the liver than control pigs (P < 0.05, Table
2). In contrast, mRNA concentration and activity of glu-
tathione peroxidase (GSH-Px) in liver were reduced by
26% and 15%, respectively, in pigs treated with clofibrate
compared to control pigs (P < 0.05, Table 2). mRNA con-
centration and activity of glutathione S-transferase (GST)
in liver cytosol and concentrations of total and reduced
glutathione in liver homogenate did not differ between
both groups of pigs (Table 2). However, the concentration
of α-tocopherol, both in absolute terms and in relative
terms, expressed per mmol of triglycerides + total choles-
terol, was lower in the liver of pigs treated with clofibrate
than in the liver of control pigs (-40%, P < 0.05) (Table 2).
The concentration of H2O2 in the liver was about 32%
lower in pigs treated with clofibrate than in control pigs (P
< 0.05, Table 3). Concentrations of lipid peroxidation
products, thiobarbituric acid-reactive substances (TBARS)
and conjugated dienes did not differ between both groups
of pigs, both in absolute terms and in relative terms,
expressed per mmol of triglycerides + total cholesterol
(Table 3).
Hepatic mRNA concentrations of p53 and c-fos did not
differ between pigs treated with clofibrate and control pigs
whereas mRNA concentrations of bax, c-jun and c-myc
were higher in pigs treated with clofibrate than in control
pigs (P < 0.05, Fig. 1). Hepatic mRNA concentrations of
bcl-XL and TNFα were lower in pigs treated with clofibrate
than in control pigs (P < 0.05, Fig. 1).
Discussion
To our knowledge, this is the first study to investigate the
effect of clofibrate treatment on peroxisome proliferation
and parameters that may be related to hepatocarcinogen-
esis in pigs, a non-proliferating species. As in many other
studies dealing with the effects of clofibrate on metabo-
lism in experimental animals, we added clofibrate to the
diet. The concentration of clofibrate in the diet of 5 g per
kg diet was adopted from other studies with pigs
[25,36,37]. The resulting daily dose of 220 mg per kg
body weight was relatively high compared with doses
used in humans for treatment of hyperlipidaemia, which
are usually in the range between 25 and 30 mg per kg
body weight.
Analysis of liver weights and number of peroxisomes
showed that treatment with clofibrate caused moderate
peroxisome proliferation in pigs. The increase in the
number of peroxisomes (+62%) observed in pigs treated
with clofibrate is of a similar order of magnitude as the
50% increase in liver peroxisome counts observed in
humans treated with clofibrate [19]. The extent of the
change in peroxisome counts in pigs is modest when com-
pared with that reported for rodents. In rodents, adminis-
tration of a dose of 200 mg clofibrate per kg body weight,
comparable with that used in this study in pigs, resulted
in a three- to five-fold increase in peroxisome counts com-
pared with controls [38]. The current study also shows
that gene expression of ACO is moderately increased by
clofibrate in pigs, which is in close accord with the mod-
erate effect of clofibrate on the peroxisome count. The
present study confirms other studies [25,36,37] which
have also shown that clofibrate causes only a relatively
weak up-regulation of PPARα target genes in pig liver. The
moderate effect of clofibrate on ACO in pigs is in strong
contrast to rodents where treatment with PPs causes a 10
to 20-fold increase in ACO expression [35,39]. Up-regula-
tion of ACO in the liver is critical because it leads to
increased production of H2O2  which causes oxidative
stress within the cell. In contrast to observations in
rodents, pigs treated with clofibrate in this study had not
a higher but a lower concentration of H2O2 in the liver.
We assume that this is due to up-regulation of catalase, the
key enzyme involved in H2O2 detoxification. In our study
both ACO and catalase were up-regulated by clofibrate to
a similar extent. Catalase has a high H2O2-detoxifying
activity and is the rate-limiting enzyme for inhibiting
H2O2 leakage from peroxisomes [40]. The finding that the
concentration of H2O2 was reduced even though the activ-BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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ity of GSH-Px, another H2O2-detoxifying enzyme local-
ised in cytosol was reduced as well, suggests that the up-
regulation of catalase was sufficient to eliminate all of the
H2O2 produced in peroxisomes. The finding of a reduced
activity of GSH-Px in liver of pigs treated with clofibrate
agrees with findings in rodents treated with PPs which
also showed a lower activity of that enzyme in the liver
[11,41].
Unsaturated fatty acids are susceptible to reactive oxygen
species and undergo oxidation. The determination of
lipid peroxides such as TBARS or conjugated dienes is
therefore a sensible method to detect oxidative stress.
Indeed, in hepatocytes of rats treated with PPs, concentra-
tions of lipid peroxidation products were increased due to
oxidative stress induced by peroxisome proliferation
[11,42]. The fact that concentrations of TBARS and conju-
gated dienes were not increased in the liver of pigs treated
with clofibrate indicates that the moderate peroxisome
proliferation was not accompanied by oxidative stress.
This indication is supported by the observation that the
concentration of reduced glutathione in the liver was also
not altered in pigs treated with clofibrate when compared
with control pigs. Glutathione plays a pivotal role in pro-
tecting cells against the noxious effects of oxidant agents,
and oxidative stress leads to enhanced oxidation of glu-
tathione, which in turn causes a lower concentration of
reduced glutathione and a lower ratio of reduced to oxi-
dized glutathione [43]. Likewise, activity of GST, an
enzyme belonging to the phase II enzymes whose reac-
tions include the addition of glutathione to electrophilic
molecules as well as the detoxification of organic
hydroperoxides, was not changed in pigs treated with clof-
ibrate. This is in contrast to rodents treated with fibrates or
other PPs that have a strongly reduced activity of GST in
the liver [44,45]. As it has been suggested that the reduced
GST activity in rodents treated with PPs is the conse-
quence of oxidative stress due to peroxisome prolifera-
tion, the finding of an unchanged activity of that enzyme
is another indication that oxidative stress did not occur in
pigs treated with clofibrate. This indication agrees with a
recent study which investigated the effect of high doses of
Table 1: Liver weights, number of peroxisomes and relative acyl-CoA oxidase mRNA concentration in the liver of pigs fed a control 
diet or a diet supplemented with 5 g clofibrate per kg for 28 days
Treatment Control (n = 9) Clofibrate (n = 9)
Liver weight (g) 673 ± 63 779 ± 63*
Liver weight (g/kg body weight) 25.9 ± 2.2 30.9 ± 2.6*
Number of peroxisomes (n/1,000 print) 366 ± 67 590 ± 116*
Acyl-CoA oxidase mRNA 1.00 ± 0.35 1.66 ± 0.41*
Results are means ± SD.
*Significantly different from control group (P < 0.05)
Table 2: Relative mRNA concentrations and activities of antioxidant enzymes and concentrations of some antioxidants in the liver of 
pigs fed a control diet or a diet supplemented with 5 g clofibrate per kg for 28 days
Treatment Control (n = 9) Clofibrate (n = 9)
Catalase
mRNA concentration 1.00 ± 0.49 1.72 ± 0.58*
Activity (U/mg protein) 0.75 ± 0.14 1.06 ± 0.16*
Glutathione peroxidase
mRNA concentration 1.00 ± 0.17 0.74 ± 0.18*
Activity (U/mg protein) 4.7 ± 0.8 4.0 ± 0.4*
Glutathione S-transferase
mRNA concentration 1.00 ± 0.41 0.90 ± 0.32
Activity (U/mg protein) 0.76 ± 0.26 0.76 ± 0.18
Superoxide dismutase
mRNA concentration 1.00 ± 0.42 1.77 ± 0.40*
Activity (U/mg protein) 43 ± 8 97 ± 13*
Glutathione, total (nmol/mg protein) 2.13 ± 0.51 1.97 ± 0.90
Glutathione, reduced (nmol/mg protein) 1.70 ± 0.50 1.67 ± 1.02
α-tocopherol
(nmol/g) 14.5 ± 2.5 8.7 ± 2.9*
[nmol/(mmol triglycerides + cholesterol)] 2.32 ± 0.40 1.36 ± 0.45*
Results are means ± SD.
*Significantly different from control group (P < 0.05)
#Relative to control (= 1.00)BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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fenofibrate and ciprofibrate in cynomolgus monkeys [24].
In that study, clofibrate treatment induced moderate
hepatic peroxisome proliferation, similar to that observed
in the pigs of the present study, but there was also mini-
mal indication of oxidative stress. It is therefore con-
cluded that even high doses of fibrates cause little
oxidative stress in the liver of non-proliferating species.
Relative mRNA concentrations of pro- and anti-apoptotic genes (bax, bcl-XL, p53, TNFα) and proto-oncogenes (c-myc, c-jun,  c-fos) in livers of pigs fed a control diet or a diet supplemented with 5 g clofibrate per kg for 28 days Figure 1
Relative mRNA concentrations of pro- and anti-apoptotic genes (bax, bcl-XL, p53, TNFα) and proto-oncogenes (c-myc, c-jun, 
c-fos) in livers of pigs fed a control diet or a diet supplemented with 5 g clofibrate per kg for 28 days. All mRNA concentrations 
were determined by real-time quantitative PCR and normalized to GAPDH. Data are reported as means ± SD with nine ani-
mals per group. Data are expressed relative to mRNA concentrations of control pigs (control = 1). * Significantly different to 
control group (P < 0.05).
Table 3: Concentration of hydrogen peroxide and lipid peroxidation products in the liver of pigs fed a control diet or a diet 
supplemented with 5 g clofibrate per kg for 28 days
Treatment Control (n = 9) Clofibrate (n = 9)
Hydrogen peroxide (fluorescence/g liver) 29,437 ± 8,361 20,078 ± 7,225*
Thiobarbituric acid-reactive substances
(nmol/g liver) 7.2 ± 1.6 7.7 ± 2.7
[nmol/(mmol triglycerides + cholesterol)] 1.15 ± 0.26 1.20 ± 0.42
Conjugated dienes (nmol/g)
(nmol/g liver) 16 ± 2 16 ± 2
[nmol/(mmol triglycerides + cholesterol)] 2.56 ± 0.32 2.49 ± 0.31
Results are means ± SD.
*Significantly different from control group (P < 0.05)BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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In the current study, pigs treated with clofibrate had
increased hepatic mRNA concentration and activity of
SOD, an enzyme that converts superoxide anions into
H2O2 and therefore contributes to increased H2O2 produc-
tion. The finding that H2O2 concentration in the liver was
reduced in spite of the increased activity of SOD is another
indication that pigs treated with fibrate had a high hepatic
H2O2-detoxifying capacity. Results from other studies
dealing with the effects of PPs on hepatic SOD are contra-
dictory. In some studies, treatment of rodents with PPs
lowered hepatic activity of SOD [41,46]; in others treat-
ment with PPs increased the activity of hepatic SOD
[47,48]. Moreover, it has been shown that different PPs
can have different effects on hepatic activity of SOD, and
that there are also differences between mice and hamsters
in the effect of PPs on SOD activity [48]. The reason for
these contradictory results is unclear and should be inves-
tigated further. As SOD is an important constituent of the
hepatic antioxidant system, an increased activity of that
enzyme observed in pigs treated with clofibrate could
contribute to a high antioxidant capacity in the liver of
these pigs.
The finding that pigs treated with clofibrate had a reduced
concentration of α-tocopherol in the liver agrees with
those of several other studies in which rodents were
treated with PPs [11,48,49]. It has been shown that the
tocopherol-lowering effect of PPs is stronger in rats than
in hamsters, suggesting that there is a correlation with the
degree of peroxisome proliferation [48]. It has been sug-
gested that the reduction of hepatic tocopherol concentra-
tion is not primarily due to oxidative stress produced by
PPs but rather to their hypolipidaemic effect [48]. Toco-
pherols are transported by lipoproteins within the body
and as hypolipidaemic drugs reduce the number of lipo-
protein particles in blood, they could also impair vitamin
E transport in the body, i.e. transport of vitamin E from
the intestine to the liver by chylomicrons. The fact that α-
tocopherol concentration was reduced in the liver of pigs
treated with clofibrate although there were no signs of oxi-
dative stress confirms the suggestion that PPs do reduce
hepatic vitamin E concentrations independent of oxida-
tive stress.
It has been shown that peroxisome proliferation leads to
hepatocellular proliferation and to inhibition of apopto-
sis, and these processes may contribute to hepatomegaly
and to hepatocarcinogenesis observed in rodents treated
with PPs [14,15]. The present study shows that clofibrate
treatment of pigs increases gene expression of the proto-
oncogenes c-jun and c-myc, which are required for entry
into the S phase of the cell cycle. These findings are in
agreement with recent studies in rodent livers and liver
cells in which treatment with WY-14,643 strongly up-reg-
ulated gene expression of proto-oncogenes [32-34]. Up-
regulation of proto-oncogenes in mouse liver cells was
followed by enhanced progression, and it has been sug-
gested that this could play a role in tumour promotion of
PPs [32]. Although up-regulation of proto-oncogenes was
smaller in pigs treated with fibrates than in rodents [32-
34], increased levels of c-jun and c-myc could have
enhanced cell proliferation, which might explain the
increased liver mass in pigs treated with clofibrate. Up-
regulation of proto-oncogenes could be a critical event
with respect to tumorigenesis. On the other hand, c-myc
can collaborate with other proteins to induce apoptosis
and sensitize cells to a variety of apoptotic triggers
[50,51]. In order to find out whether clofibrate treatment
in pigs could have altered apoptosis, we determined
mRNA concentrations of bax, bcl-XL and p53 in the liver.
Genes of the bcl-2 family have anti-apoptotic effects,
which is antagonized by bax. The bcl-2/bax ratio is a key
factor for determining apoptosis. When bcl-2 is expressed
excessively, bcl-2-bax heterogenous dimer predominates,
thus inhibiting apoptosis [52]. When bax is expressed
excessively, bax-bax homogenous dimer or monomer pre-
dominates, thus promoting apoptosis. p53 is a tumour
suppressor which exerts control over cell cycling by con-
trolling the progression through the G1 phase [53]. Gen-
otoxic stress or DNA damage leads to nuclear
accumulation of p53, which in turn activates the tran-
scription of several genes involved in DNA repair or apop-
tosis, including bcl-2 [54]. We did not directly determine
apoptosis in the liver of piglets but the finding that expres-
sion of bax was up-regulated in pigs treated with clofibrate
while expression of bcl-XL was reduced, together with the
observation of unchanged p53 expression suggests that
apoptosis was not inhibited but could instead have been
increased in these pigs. This suggestion agrees with recent
studies which have shown that clofibrate induces apopto-
sis in human and rat hepatoma cells [55-59]. In agree-
ment with our study, a recent study showed that treatment
with WY 14,643 up-regulates pro-apoptotic genes and
down regulates anti-apoptotic genes in the liver of mice,
an effect which did not occur in PPARα-null mice [60]. In
that study, it was also demonstrated that PPARα activa-
tion increases the sensitivity of liver towards apoptosis by
Jo-2, an inducer of hepatic apoptosis. Therefore, it has
been suggested that PPARα could serve as a pharmacolog-
ical target in diseases where apoptosis is a contributing
feature [60,61].
In a recent study in rats it was found that NF-KB is acti-
vated by WY-14,643, probably due to oxidative stress
caused by peroxisome proliferation [62]. It has been dem-
onstrated that NF-KB is essential for inducing cell prolifer-
ation and hepatocarcinogenesis in rodents treated with
fibrates [28,29]. The finding that mRNA concentration of
TNFα, a target gene of NF-κB, was reduced in liver of pigs
treated with clofibrate compared to control pigs indicatesBMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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that clofibrate did not activate the NF-KB pathway in these
animals. This finding may be related to the observation
that clofibrate treatment did not cause oxidative stress in
pigs, in contrast to rats. The finding that WY-14,643 did
not activate the NF-KB pathway in hamsters either [62]
suggests that PPs activate NF-KB only in species that are
responsive to PP induced hepatocarcinogenesis.
Conclusion
Treatment with clofibrate at doses higher than those used
for hypolipidaemic treatment in humans causes moderate
peroxisome proliferation in the liver of pigs. Determina-
tion of the concentration of H2O2 and lipid peroxidation
products indicates that this did not produce oxidative
stress. Determination of mRNA concentrations of pro-
and anti-apoptotic genes in the liver indicates that clofi-
brate treatment did also not inhibit but rather stimulated
apoptosis in these animals. Up-regulation of the proto-
oncogenes c-myc and c-jun in the liver, however, could be
a critical event with respect to carcinogenesis, which
deserves further investigation in future studies. As the
extent of peroxisome proliferation by clofibrate was simi-
lar to that observed in humans, the pig can be regarded as
a useful model for the investigating the effects of PPs on
liver function and hepatocarcinogenesis.
Methods
Animals and treatments
Eighteen male 8-week-old crossbred pigs [(German Lan-
drace × Large White) × Pietrain] were kept in a room
under controlled conditions at 23 ± 2°C and 55 ± 5% rel-
ative humidity with light from 0600 to 1800 h. One day
before the start of the experimental feeding period the pigs
were weighed and randomly assigned to two groups with
body weights of 12.0 ± 1.1 kg in the control group and
11.9 ± 0.6 kg in the treatment group. Both groups of pigs
received a nutritionally adequate dry diet for growing pigs
(according to [63]) containing (in g/kg) wheat (400), soy-
bean meal (230), wheat bran (150), barley (100), sun-
flower oil (90) and mineral premix including L-lysine,
DL-methionine and L-threonine (30). This diet contained
14.4 MJ metabolizable energy and 185 g crude protein per
kg. The whole daily amount of diet was administered once
at 8.00 h. Diet intake was controlled, and each animal in
the experiment was offered an identical amount of diet
per day. The amount of diet administered was about 15%
below that consumed ad-libitum by pigs of a similar
weight (as assessed in a previous study). Therefore, the
diet offered was completely taken up by all pigs in the
experiment. During feeding period, the amount of diet
offered each day was increased continuously from 400 to
1,200 g. Pigs of both groups received the same diet. How-
ever, pigs of the treatment group were given additionally
5 g clofibrate per kg diet which was freshly given onto the
diet on each day. The pigs had free access to water via nip-
ple drinking systems. The experimental diets were admin-
istered for 28 d. All experimental procedures described
followed established guidelines for the care and use of
laboratory animals and were approved by the local veter-
inary office.
Sample collection
After completion of the feeding period the piglets were
captive-bolt stunned and exsanguinated. Four hours
before euthanasia each pig was fed its respective diet. After
killing, blood was collected into heparinized polyethyl-
ene tubes. Plasma was obtained by centrifugation of the
blood (1,100 × g; 10 min; 4°C). The liver was dissected
and weighed and samples were stored at -80°C until anal-
ysis. For preparation of liver homogenate, one g of liver
was homogenized in 10 mL of 0.1 M phosphate buffer,
pH 7.4, containing 0.25 M sucrose using a Potter-Elve-
hjem homogenizer. Homogenates were centrifuged at
1,000 × g for 10 min at 4°C and the supernatant was cen-
trifuged at 15,000 × g for 15 min again. The supernatant
of that centrifugation was collected and centrifuged at
105,000 × g for 60 min to yield the cytosolic fraction.
Liver homogenates and cytosolic fraction were stored at -
20°C for further analysis. Protein concentrations of liver
homogenates and cytosol were determined with the bicin-
choninic acid reagent according to the supplier's protocol
(Interchim, Montelucon, France) using bovine serum
albumin as the standard.
RT-PCR analysis
Total RNA from liver tissue was isolated by TRIzol reagent
(Invitrogen, Karlsruhe, Germany) following the manufac-
turer's protocol, resuspended in diethyl pyrocarbonate-
treated water and stored at -80°C until use. The concentra-
tion and purity of total RNA was determined by ultraviolet
absorbance at 260 and 280 nm (SpectraFluor Plus; Tecan,
Crailsheim, Germany). The quality of all RNA samples
was assessed by agarose gel electrophoresis. cDNA was
prepared from total RNA (1.2 μg) by reverse transcription
using M-MuLV Reverse Transcriptase (MBI Fermentas, St.
Leon-Rot, Germany) and oligo(dT)18 primers (Operon
Biotechnologies, Cologne, Germany). The mRNA concen-
tration of genes was measured by realtime detection PCR
using SYBR® Green I and a MJ Research Opticon system
(Biozym Diagnostik GmbH, Oldendorf, Germany). Real-
time detection PCR was performed with 1.25 U Taq DNA
polymerase (Promega, Mannheim, Germany), 500 μM
dNTPs and 26.7 pmol of the specific primers (Operon
Biotechnologies, Cologne, Germany; Table 4). Annealing
temperature for all primers was 60°C. Amplification effi-
ciencies for all primer pairs were determined by template
dilution series. Calculation of the relative mRNA concen-
tration was made using the amplification efficiencies and
the Ct values [64]. Glyceraldehyde 3-phosphate dehydro-BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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genase (GAPDH) was used as housekeeping gene for nor-
malization.
Enzyme assays
SOD in liver cytosol was determined with pyrogallol as
the substrate [65]. One unit of SOD activity is defined as
the amount of enzyme required to inhibit the autoxida-
tion of pyrogallol by 50%. The activity of GSH-Px in liver
cytosol was determined with t-butyl hydroperoxide as
substrate [66]. One unit of GSH-Px activity is defined as
one μmol reduced β-nicotinamide adenine dinucleotide
phosphate oxidized per min. The activity of GST was
determined using 1-chloro-2,4-dinitrobenzene as sub-
strate [67]. One unit of GST is defined as one nmol sub-
strate consumed per min. Catalase activity in liver
homogenate was determined using hydrogen peroxide as
substrate [68]. One unit of catalase activity is defined as
the amount consuming 1 mmol hydrogen peroxide per
min. GSH concentration in liver homogenates was deter-
mined according to Griffith [69].
Determination of conjugated dienes, TBARS, α-
tocopherol, cholesterol and triglycerides in the liver
Lipids from liver were extracted using a mixture of n-hex-
ane and isopropanol (3:2, v/v). After drying the lipid
extracts, 1 mg of extract was dissolved in 1 ml n-hexane.
The concentrations of conjugated dienes were calculated
by using the molar extinction coefficient for conjugated
dienes at 234 nm (ε = 29,500 mol × cm-1). The concentra-
tions of TBARS were measured with thiobarbituric acid as
reagent in a fluorimetric assay [70]. Concentration of α-
tocopherol in liver tissue was determined by HPLC with
fluorescence detection [70]. For determination of triglyc-
erides and total cholesterol, an aliquot of the lipid extract
was dried, and the dried lipids were dissolved with Triton
X-100 [71]. The concentrations of cholesterol and triglyc-
erides were determined using enzymatic kits (Cat.-No.
113009990314 for cholesterol and Cat.-No.
157609990314 for triglycerides, Ecoline S+, DiaSys,
Holzheim, Germany).
Determination of H2O2
To determine the H2O2 content in liver homogenates, a
method [72] described for cell culture systems was modi-
fied, using dihydrorhodamine 123 (DHR) as substrate.
Homogenates were incubated with 27.5 μM DHR for 1 h
at 37°C in a final volume of 400 μl. After incubation, the
fluorescence of rhodamine 123, the oxidation product of
DHR, was measured (excitation wavelength: 485 nm,
emission wavelength: 538 nm). As previously shown [73],
this test is specific for H2O2 as DHR is specifially oxidized
by H2O2.
Transmission electron microscopy
Small liver segments of three animals per group were fixed
immediately after dissection of the liver with 3% glutaral-
dehyde in 0.1 M sodium cacodylate buffer (SCB, pH 7.2)
for 3 hours at room temperature, washed with SCB, post-
fixed with 1% osmiumtetroxide in SCB, dehydrated in a
graded ethanol series, and embedded in epoxy resin [74].
The material was sectioned with an ultramicrotome S
(Leica, Bensheim, Germany). Ultrathin sections (80 nm)
were transferred to coated copper grids and poststained
with uranyl acetate and lead citrate. The sections were
observed with an EM 900 transmission electron micro-
scope (Zeiss SMT, Oberkochen, Germany) at an accelera-
tion voltage of 80 kV. Electron micrographs were taken
with a slow scan camera (TRS, Dünzelbach, Germany).
Table 4: Sequences of specific primers used for RT-PCR
Gene (NCBI Genbank) Forward Primer Reverse Primer Size, bp
ACO (AF185048) CTCGCAGACCCAGATGAAAT TCCAAGCCTCGAAGATGAGT 218
bax (AJ606301) CGAACTGATCAGGACCATCA ACAGCCCATCTTCTTCCAGA 190
bcl-XL (NM_214285) GAAACCCCTAGTGCCATCAA GGGACGTCAGGTCACTGAAT 196
Catalase (NM_214301) CAGCTTTAGTGCTCCCGAAC AGATGACCCGCAATGTTCTC 180
c-fos (Y14808) CTGACACACTCCAAGCGGTA CTTCTCCTTCAGGTTGG 209
c-jun (NM_213880) CAGAGCATGACCCTGAACCT TTCTTGGGGCATAGGAACTG 200
c-myc (NM_001005154) AATGTCTTGGAACGCCAGAG CAACTGTTCTCGCCTCTTCC 204
GAPDH (AF017079) AGGGGCTCTCCAGAACATCA
TCC
TCGCGTGCTCTTGCTGGGGT
TGG
446
GSH-Px (NM_214201) CAAGAATGGGGAGATCCTGA GATAAACTTGGGGTCGGTCA 190
GST (NM_214300) TTTTTGCCAACCCAGAAGAC GGGGTGTCAAATACGCAATC 246
p53 (NM_214145) GCGAGTATTTCACCCTCCAG TCAGGCCCTTCTCTCTTGAA 199
PPARα (DQ437887) CAGCCTCCAGCCCCTCGTC GCGGTCTCGGCATCTTCTAG
G
381
SOD (AF396674) TCCATGTCCATCAGTTTGGA CTGCCCAAGTCATCTGGTTT 250
TNFα (X57321) CCCCTGTCCATCCCTTTATT AAGCCCCAGTTCCAATTCTT 200
Abbreviations: ACO, acyl-CoA oxidase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSH-Px, glutathione peroxidase; GST, glutathione S-
transferase; SOD, superoxide dismutase; TNFα, tumor necrosis factor α.BMC Pharmacology 2007, 7:6 http://www.biomedcentral.com/1471-2210/7/6
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Peroxisomes were counted in 1,000 different regions per
liver sample for each animal at a screen (12,000-fold mag-
nification).
Statistics
The results were analyzed using Minitab (State College,
Pa, USA) statistical software (release 13). Statistical signif-
icance of differences between control group and treatment
group was evaluated using Student's t-test. Mean values
were considered significantly different for P < 0.05.
List of abbreviations
ACO, acyl-CoA oxidase; DHR, dihydrorhodamine;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
GSH-Px, glutathione peroxidase; GST, glutathione S-
transferase; NF-KB, nuclear factor KB; PPARα, peroxisome
proliferator-activated receptor α; PPs, peroxisome prolif-
erators; SCB, sodium cacodylate buffer; SOD, superoxide
dismutase; TBARS, thiobarbituric acid-reactive sub-
stances; TNFα, tumor necrosis factor α.
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